TOP TEN perturbations for 39157_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39157_at
Selected probe(set): 217406_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39157_at (217406_at) across 6672 perturbations tested by GENEVESTIGATOR:
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.4012489Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.3831892Number of Samples:3 / 3
| Experimental | influenza virus study 10 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.2888422Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/pH1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
Langerhans cell histiocytosis study 4 / normal tonsillar T-lymphocyte sample
Relative Expression (log2-ratio):1.2836723Number of Samples:7 / 4
| Experimental | Langerhans cell histiocytosis study 4 |
| CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease). | |
| Control | normal tonsillar T-lymphocyte sample |
| Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue. |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):-1.2813492Number of Samples:4 / 2
| Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.2583942Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):1.1414423Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
systemic onset JIA study 6 (baseline; placebo) / normal blood sample
Relative Expression (log2-ratio):-1.0976076Number of Samples:22 / 22
| Experimental | systemic onset JIA study 6 (baseline; placebo) |
| Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted. | |
| Control | normal blood sample |
| Whole blood samples collected from healthy volunteers. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):1.0595112Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
pediatric septic shock study 3 (neonatal; subclass A) / pediatric septic shock study 3 (neonatal)
Relative Expression (log2-ratio):0.9955778Number of Samples:9 / 7
| Experimental | pediatric septic shock study 3 (neonatal; subclass A) |
| Whole blood samples obtained from neonatal children (< 28 days of age) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Four neonatal children did not survive. All neonatal children were born after full-term gestations. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (neonatal) |
| Whole blood obtained from neonatal children (< 28 days of age) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Three children did not survive. All neonatal children were born after full-term gestations. |